17p13.3 is one of the chromosomal regions most frequently affected by allelic loss in a variety of human neoplasms including lung cancer. A number of loss of heterozygosity (LOH) analyses have suggested the existence of a tumor suppressor gene at 17p13.3, distal to the p53 locus at 17p13.1. In the present study, we characterized a homozygous deletion at 17p13.3 in a small cell lung cancer cell line by constructing a bacterial artificial chromosome (BAC) contig and a restriction map surrounding the region, as well as by utilizing publicly available draft sequences. We defined the breakpoint, assigned and analysed two known genes, 14-3-3e and CRK, and a novel gene LOST1 within or at the end of the homozygous deletion of about 170 kb in size. Marked reduction of LOST1 expression was detected in 69% (11/ 16) of lung cancer specimens by quantitative real-time RT-PCR, while significant DNA hypermethylation was observed at the 5 0 end of the LOST1 gene in four of six lung cancer cell lines with negligible LOST1 expression. We also show here that a polymorphic marker D17S1174, which resides within the homozygous deletion, was apparently located in the middle of the minimum LOH region, providing further supportive evidence for the presence of a tumor suppressor gene(s) in this region.
Introduction
Accumulating evidence suggests that a series of genetic alterations such as activation of oncogenes and inactivation of tumor suppressor genes are involved in the pathogenesis of lung cancer (Minna et al., 1997) . According to Knudson's two-hit theory, tumor suppressor genes are inactivated by a recessive mutation in one allele and loss of the other allele retaining wild-type function (Knudson, 1971) . Allelic loss is therefore considered to be a hallmark of chromosomal regions harboring tumor suppressor genes. Cytogenetic and molecular analyses of lung cancers have revealed frequent occurrence of multiple chromosomal deletions including 3p, 5q, 8p, 9p, 11p, 13q, 17p, 18q and 22q (Minna et al., 1997) .
It has been shown that 17p is among the most frequently affected chromosomal regions in lung cancer (Yokota et al., 1987) . We and others have clearly provided evidence indicating that the p53 gene at 17p13.1 is a genuine molecular target for the frequent 17p deletions in lung cancer (Takahashi et al., 1989 (Takahashi et al., , 1992 . Interestingly, however, our detailed deletion mapping analysis of 17p with special reference to the p53 gene status revealed the presence of an independent, commonly deleted region(s) at 17p13.3, suggesting the existence of an additional tumor suppressor gene(s) distal to the p53 gene (Konishi et al., 1998) . Frequent allelic loss at 17p13.3 independent of the p53 locus has also been reported to be common in a variety of other human malignancies including breast, ovarian and hepatocellular carcinomas as well as neural tumors (Coles et al., 1990; Fujimori et al., 1991; Biegel et al., 1992; Cogen et al., 1992; Saxena et al., 1992; Phillips et al., 1996; Schultz et al., 1996) .
Our subsequent search for a clue to the isolation of a tumor suppressor gene from this region resulted in the identification of homozygous deletion of the 14-3-3e gene in two small cell lung cancer (SCLC) cell lines, which had been established from distinct metastatic sites of the same patient at different treatment periods (Konishi et al., 2002) . Consistent with the notion that the 14-3-3 family proteins play a role in imposing G2 arrest in response to DNA damage through cdc2 inactivation, we were able to show that introduction of 14-3-3e into the lung cancer cell line with 14-3-3e homozygous deletion significantly restored G2 checkpoint impairment. Together with prevalent perturbation of the G1 and M phase checkpoints in lung cancers (Takahashi et al., 1989 Nomoto et al., 1999) , the involvement of the 14-3-3e gene within the homozygous deletions was of interest. However, the possibility that a systematic, detailed investigation of the homozygously deleted region may yield an additional gene that plays a crucial role in the pathogenesis of lung cancer was not precluded.
In the present study, we constructed a bacterial artificial chromosome (BAC) contig and a restriction map surrounding the homozygously deleted region, and defined the breakpoints. One novel and two known genes were found within the homozygous deletion and analysed in detail. We also provide further supportive evidence for the presence of a tumor suppressor gene (s) in this region as well as in a more centromeric region between D17S5 and D17S379.
Results

Construction and characterization of a contig covering the homozygous deletion at 17p13.3
We previously screened 65 lung cancer cell lines with the aid of nine markers mapped within the commonly deleted region at 17p13.3, and found that a sequencetagged site (STS) corresponding to the 14-3-3e gene was involved in a homozygously deleted region in two SCLC cell lines (Konishi et al., 2002) . The two cell lines, ACC-LC-48 and ACC-LC-52, were originated from distinct metastatic sites of the same patient at the different treatment periods, suggesting the occurrence of the homozygous deletion before metastasis in vivo. We initiated this study by carrying out the BLAST search against the National Center for Biotechnology Information (NCBI) Nucleotide Sequence Databases using complementary DNA (cDNA) sequence of 14-3-3e. This in silico screening resulted in the identification of two BAC clones, RPCI-11-818O24 (818O24; AC032044.9) and RPCI-11-241L15 (241L15; AC025071.3) via the high throughput genomic sequences (HTGS) section of the databases. These two BACs widely overlapped each other, while 818O24 harbored the CRK gene as well as 14-3-3e. Further investigation of these BACs using public databases, however, showed uncertainty with regard to their chromosomal location, that is, the assignment of these two BACs had been repeatedly changed through revisions to the public databases. Although 14-3-3e and CRK had originally been assigned centromeric to ABR in 17p13.3, data from NCBI built 28 mapped these BACs and genes at 17q21.32, whereas according to NCBI built 29 they were located at close proximity to the distal end of 17p. A large physical map of 17p13.3 by McHale et al. (2000) spanned the frequent LOH region at 17p13.3 but did not contain 14-3-3e and CRK.
To define precisely the genomic context surrounding the homozygous deletion, we constructed our own genomic contig covering the homozygous deletion. Polymerase chain reaction (PCR) screening for yeast artificial chromosome (YAC)/BAC DNA pool libraries were performed using three STS markers including 14-3-3e exon 1, CRK exon 3 and D17S1174, which yielded five YAC and three BAC clones mapped at the homozygously deleted region. The insert end sequences for each YAC/BAC clone were determined and utilized to generate STS markers. All five YAC clones were apparently chimeric, but they were nevertheless useful to align BAC clones as shown in Figure 1a . BLAST search for each marker on this contig revealed that 818O24 and 241L15, sources of the NCBI sequence information, were just next to the previously unconnected three BACs, that is, 407I21 (AF322450.1), RPCI-11-107N19 (AC006405.1) and RPCI-11-433M14 (AC068936.2) ( Figure 1a ). These three BACs harbored MYO1C, SKIP, PITPN, SREC, RILP and PRP8, all of which had consistently been assigned to 17p13.3. In addition, YAC/BAC end markers on our contig were surveyed by PCR using the Human Chromosome 17 Regional To further define the extent of the homozygous deletion, we carried out PCR examinations for all of the STS markers on our contig map using genomic DNAs (gDNAs) from ACC-LC-48 and ACC-LC-52 as templates. The result of the PCR examination revealed the involvement of all six exons of the 14-3-3e gene, CRK exon 3 and microsatellite marker D17S1174 within the homozygous deletion in ACC-LC-48 and ACC-LC-52, whereas CRK exons 1 and 2 were excluded ( Figure  1a and b).
Restriction enzyme mapping and size estimation of the homozygous deletion DNA sequences of 818O24 and 241L15 covering the homozygous deletion had been made available as collections of 10-30 unordered pieces accompanied by unknown lengths of gaps depending on the time points during the course of this study, and there are still many gaps of uncertain length. We thus conducted restriction enzyme mapping for CITB-105A24 (105A24), GS1-224gO1 (224gO1) and CITB-442O5 (442O5), with five rare-cutting restriction enzymes including MluI, NruI, NotI, NheI and SalI using cDNA probes for 14-3-3e and CRK (Figure 2 ). Also, we generated STS markers at the MluI and NotI sites on 442O5 (Table 1) . As a result, the size of the homozygous deletion could be estimated as approximately 170 kb. Consequently, MYOIC, SKIP and PITPN were demonstrated to reside on 105A24 and 224g01, but these genes were excluded from the homozygously deleted region (Figure 2 ).
Search for a novel gene at the homozygous deletion region
To investigate as yet unidentified transcriptional units in the homozygous deletion, we conducted gene predictions based on the draft sequence of 818O24 using GENSCAN, Grail, FGENESH and HMMgene. Although four exons (termed as PE1-PE4) of a potential novel gene(s) were predicted, screening against an adult lung cDNA library and a fetal brain cDNA library with these predicted exons as probes yielded no cDNA clones.
We also searched for UniGene clusters, which reside on the BAC 818O24 draft sequence, using the NCBI MapViewer program. One of seven UniGene clusters on 818O24, Hs. 146059, appeared to represent 3 0 end of an unknown transcriptional unit, while others agreed with exonic or intronic sequences of either 14-3-3e or CRK. We purchased three cDNA clones corresponding to Hs. 146059 (C20774, C44602 and C44924 in GeneConnection Discovery Clones; Stratagene) and determined the sequence. On further assessment by means of the exonconnection PCR, 5 0 rapid amplification of cDNA ends (RACE) and RNA protection assay, this transcriptional unit was shown to consist of three exons with a putative open reading frame (ORF) encoding 177 amino acids (Figure 3a, b) . We designated this novel gene LOST1 (LOcated at Seventeen-p-Thirteen point three 1).
Simple Modular Architecture Research Tool (SMART) predicted two transmembrane domains close to the C-terminus of LOST1 (Figure 3c ), while hydrophobicity analysis consistently showed the presence of two hydrophobic peaks at the regions annotated as transmembrane domains (data not shown). Protein-protein BLAST search against the NCBI Peptide Sequence Databases identified an unknown human protein, namely 'protein for MGC:9889' (AAH11405.1) as the only registration with homology to LOST1 (Figure 3c ). Strong homology was detected at AA101-AA176 in the C-terminal region of LOST1, which included the two transmembrane domains (45% of identity; E value ¼ 2 Â 10
À4
). We performed 3 0 RACE for LOST1 and found two messenger RNA isoforms in agreement with the existence of two polyadenylation signals (AATAAA) (Figure 3a) . A relatively high expression was observed in muscular organs such as the heart, smooth muscle and skeletal muscle, while LOST1 was also modestly expressed in the brain and the bronchus (Figure 4a ). Southern blot analysis demonstrated rearranged bands in ACC-LC-48 and ACC-LC-52, indicating that LOST1 had been disrupted by the homozygous deletion (Figure 4b ). 
Mutational analysis of the three genes within the homozygous deletion
We conducted mutational analysis of genes mapped within the homozygous deletion. The entire ORF of the 14-3-3e and CRK genes were analysed in 28 lung cancer cell lines (14 SCLCs, five adenocarcinomas, five squamous cell carcinomas and four large cell carcinomas) as well as in 40 lung cancer specimens (13 SCLCs, 15 adenocarcinomas, 11 squamous cell carcinomas and one large cell carcinoma) by RT-PCR-single-strand conformation polymorphism (SSCP) analysis followed by sequencing of the shifted bands. Six breast cancer cell lines and seven hepatocellular carcinoma cell lines were additionally included in the examination. In the 14-3-3e gene, an identical sequence variation at codon 252 with no amino acid substitution was detected in a squamous cell carcinoma cell line QG56 and an adenocarcinoma (Table 2) . As for the CRK gene, frequent and rare silent polymorphisms were detected at codons 17 and 38, respectively. In a hepatocellular carcinoma cell line PLC/PRF5, nucleotide substitutions were detected at codon 68 (CGC to CGG, no amino acid change). Mutational analysis of the entire ORF of the LOST1 gene was conducted by direct sequencing following PCR amplification of each exon using gDNAs from 41 lung cancer cell lines (16 SCLCs, 13 adenocarcinomas, seven squamous cell carcinomas and five large cell carcinomas) as well as 40 lung cancer cases (10 SCLCs, 15 adenocarcinomas, 12 squamous cell carcinomas and three large cell carcinomas). This examination identified several SNPs, all of which were located at the Nterminal half of exon 1 (Table 2 ). All the variant alleles detected in the tumor tissues were also present in the corresponding normal lungs. No somatic mutations were identified in any of the three genes, indicating that these genes are not frequent targets for somatic mutations in lung cancer.
Expression analysis of the three genes within the homozygous deletion
We analysed the expression of the three genes mapped within the homozygous deletion using 16 lung cancer tissues (three SCLCs, six adenocarcinomas, six squamous cell carcinomas and one large cell carcinoma). The expression of the 14-3-3e gene and the CRK gene in lung Figure 5 ).
Methylation analysis of the LOST1 gene
The identification of negligible expression of the LOST1 gene in a significant fraction of lung cancer specimens prompted us to examine the DNA methylation status of LOST1. Genomic DNAs from six lung cancer cell lines with negligible LOST1 expression, as well as those from two normal lung tissues, were examined. Following sodium bisulfite conversion, genomic DNAs encompassing the 5 0 end of the LOST1 gene were amplified and cloned for sequence determination. Four of the six lung cancer cell lines demonstrated increased DNA methylation at CpG sites (67, 80, 83 and 83%, respectively), whereas normal lung tissues, which express LOST1 showed methylation at only 33-37% (10/30 and 11/30, respectively) of the CpG sites examined (Figure 6 ). 
Isolation and sequencing of breakpoints of the homozygous deletion
To further localize the centromeric border of the homozygous deletion, we generated five STS markers within CRK intron 2. The PCR examinations revealed that only the most centromeric marker was retained in ACC-LC-48. Thus, the forward primer for this STS marker and the PE1-F primer, which was presumed to be very close to the telomeric end of the homozygous deletion, were utilized for PCR with gDNAs, resulting in the robust amplification of PCR products of 1918 bp exclusively in ACC-LC-48 and ACC-LC-52. Duplex PCR using a primer pair encompassing the homozygous deletion as well as that of p53 indicated that ACC-LC-48 and ACC-LC-52 possess interstitial deletions (Figure 7a ). Sequence analysis of both ends of the homozygous deletion revealed the presence of a Homozygous deletion at 17p13.3 in lung cancer H Konishi el al potential 2 bp short direct repeat as well as a set of inverted repeats at both sides of the breakpoints (Figure 7b ), suggesting that either of these homologous repeats may have played a role in the generation of this interstitial deletion.
LOH study at D17S1174 in combination with other 17p13.3 markers in cases of primary lung cancer
We assessed LOH status specifically of a genomic region involved in the homozygous deletion in 100 cases of primary lung cancer. D17S1174 was chosen for this study, since this marker was found to be the only microsatellite marker within 818O24 in the computational search in the NCBI UniSTS database. The result was analysed with reference to the LOH data for nine other polymorphic markers at 17p, which had been obtained in our previous study (Konishi et al., 1998) . D17S1174 showed LOH in 57% of the cases (90% in SCLCs, 48% in adenocarcinomas, 58% in squamous cell carcinomas, and 75% in large cell carcinomas), being the most frequently affected marker at 17p13.3 along with D17S5 (56%). In addition, D17S1174 in case 94 and D17S5 in case 64 showed apparent retention of heterozygosity flanked by LOH at closely mapped loci, a potential indication of the presence of homozygous deletions (Cairns et al., 1994) .
Detailed inspection of the LOH analysis data identified 31 cases with LOH at 17p13.3 despite apparent retention of heterozygosity at the p53 locus and/or at least one or more markers mapped between p53 and the 17p13.3 markers (Figure 8 ). Consequently, two chromosomal regions surrounding D17S1174 and D17S379 were found to be two independent minimum deleted regions, while five cases (22, 23, 49, 66 and 100) showing small deletions harboring either D17S1174 or D17S379. Confinement of the minimum deleted regions to small regions surrounding D17S1174 or D17S379 provided further support for the presence of tumor suppressor genes involved in lung carcinogenesis.
Discussion
Detailed analyses of homozygous deletions have provided important clues to the isolation of a number of tumor suppressor genes including RB, p16, FHIT, RASSF1, Smad4 and PTEN/MMAC1 (Friend et al., 1986; Lee et al., 1987; Kamb et al., 1994; Nobori et al., 1994; Hahn et al., 1996; Ohta et al., 1996; Li et al., 1997; Steck et al., 1997; Dammann et al., 2000; Burbee et al., 2001 ). In the current study, we characterized a homozygous deletion at 17p13.3 by analysing YAC and BAC clones covering the region as well as by utilizing publicly available draft sequences. We also assigned one novel and two known genes within or at the end of the homozygous deletion of about 170 kb in size. LOH analysis with primary lung cancer specimens revealed that a polymorphic marker D17S1174, which resides within the homozygous deletion, was apparently Homozygous deletion at 17p13.3 in lung cancer H Konishi el al located in the middle of the minimum LOH region, supporting the notion that the small chromosomal region harboring the homozygous deletion may contain an important gene in terms of the molecular pathogenesis of human lung cancer. 17p13.3 is known to be a chromosomal region frequently affected in a variety of neoplasms. A number of LOH studies have demonstrated the existence of commonly deleted regions at 17p13.3, which is independent of and distal to the p53 locus at 17p13.1 (Coles et al., 1990; Fujimori et al., 1991; Biegel et al., 1992; Cogen et al., 1992; Saxena et al., 1992; Phillips et al., 1996; Schultz et al., 1996; Konishi et al., 1998) . However, only two homozygous deletions have been found in this region in any type of human cancers (Phillips et al., 1996; Haataja et al., 1997) . Our report presented here represents the third such example and the first detailed molecular analysis of a homozygous deletion at 17p13.3 in combination with systematic screening of the genes residing in this region of great interest.
Two genomic regions at 17p13.3 have been reported thus far to harbor potential tumor suppressor genes in different types of malignancies. A region around D17S5 (YNZ22) had previously been shown to exhibit the highest frequency of LOH in ovarian cancer (Phillips et al., 1996; Schultz et al., 1996) , while D17S5 was also found to be one of the most frequently affected 17p13.3 markers in lung cancers (Konishi et al., 1998) . The other frequently affected region is a subtelomeric region of 17p13.3 encompassing D17S34, D17S926 and D17S824, which corresponds to the minimum deleted regions in several types of neoplasms such as neurogenic tumors and hepatocellular carcinoma (Biegel et al., 1992; Cogen et al., 1992; Saxena et al., 1992; Zhao et al., 2001) , while a fine deletion mapping study in breast cancer has demonstrated complex distribution of commonly affected regions often involving either D17S5 locus or the subtelomeric 17p13.3 region (Stack et al., 1995) . Several candidate genes, which may account for the high frequency of LOH, have been reported including HIC-1, OVCA1/DPH2L and ROX/Mnt around D17S5 (Wales et al., 1995; Schultz et al., 1996; Hurlin et al., 1997; Meroni et al., 1997) as well as HCCS1 recently isolated from a region near D17S926 (Zhao et al., 2001) .
LOH analysis of a series of 100 cases of lung cancer in this study demonstrated that the D17S1174 locus within the homozygous deletion was affected at the highest frequency among the 17p markers we have thus far examined, while three of the 100 cases exhibited LOH exclusively at D17S1174. We note that this chromosomal region has not been delineated thus far as a frequently affected minimum region of LOH, which is located roughly 1 Mb apart from the two regions described above. Taken together, these data suggest Figure 8 Extent of small LOHs confined to 17p13.3 in a panel of 100 cases of lung cancer. The extent is indicated with gray boxes. The data in this figure were generated by combining the present data with D17S1174, which was found here to be contained in the homozygous deletion, as well as data from our previous study. AD, adenocarcinoma; SQ, squamous cell carcinoma; LA, large cell carcinoma. Two representative cases exhibiting LOH exclusively at the D17S1174 locus are shown on the right. Open and solid arrowheads refer to larger and smaller alleles, respectively. N, normal; T, tumor Homozygous deletion at 17p13.3 in lung cancer H Konishi el al the existence of a potential tumor suppressor gene in lung cancer in this genomic region.
In this study, we conducted an extensive search for genes contained within the homozygous deletion, resulting in the identification of three genes. A novel gene, named LOST1, was shown to be disrupted at the middle of exon 1 by the homozygous deletion, resulting in the perturbation of its coding capacity. Our preliminary examination failed to identify somatic mutations within the ORF of LOST1 as well as in those of two other genes residing in the homozygous deletion, that is, 14-3-3e and CRK. Interestingly, however, significantly reduced expression of the LOST1 gene was detected in 69% (11/16) of lung cancer specimens, suggesting that loss of LOST1 expression might play a role in the pathogenesis of lung cancers. Our methylation analysis suggested the potential relation between loss of LOST1 expression and aberrantly increased hypermethylation of the LOST1 gene locus in a subset of lung cancer cell lines. Although the silencing mechanism for cell lines without LOST1 hypermethylation remains to be elucidated, it is of note that abnormal chromatin conformation alone has been shown to be responsible for loss of TGF-b type II receptor expression at least in a fraction of lung cancer cell lines (Osada et al., 2001) . It is also possible that expression of a gene(s) within or close to the homozygous deletion including LOST1 may be regulated by a transcriptional regulatory element such as an enhancer residing in this homozygous deletion, while subtle alterations of such an element might have been overlooked because of our ORF-focused search for mutations. Alternatively, considering that the lack of 14-3-3e appeared to be responsible for the defective G2 checkpoint in ACC-LC-48 (Konishi et al., 2002) , it is possible that 14-3-3e may have played a primary role in the clonal expansion of lung cancer cells carrying the homozygous deletion. It has not been formally precluded that the chromosomal region surrounding D17S1174 but outside the homozygously deleted region might contain a gene with frequent mutations, and that 17p13.3 might harbor multiple lung cancer-related genes like 3p21.3 with multiple candidate tumor suppressor genes including RASSF1A, FUS1, SEMA3B and H37/ RBM5 (Dammann et al., 2000; Lerman and Minna, 2000; Burbee et al., 2001; Kondo et al., 2001; Tomizawa et al., 2001; Ji et al., 2002; Oh et al., 2002) . It is of note that candidate genes thus far identified at 3p21.3 show low frequencies of somatic mutations with frequently reduced expression owing to hypermethylation at the promoter regions (Lerman and Minna, 2000) . Taken together, further functional analysis of LOST1 as well as a search for genes in the surrounding region will prove interesting and may reveal intriguing features of LOST1 and an as yet unrevealed tumor suppressor candidate(s) in terms of lung carcinogenesis.
An additional minimum LOH region at 17p13.3 was also demonstrated to exist around D17S379. It is notable that a putative tumor suppressor gene, HIC-1, resides between D17S379 and the above-mentioned D17S5 locus (Wales et al., 1995) . Although frequent somatic mutations in tumor DNA have not been detected so far, HIC-1 possesses several lines of features, which are in line with its role as a tumor suppressor gene, including reduced expression because of tumor-specific hypermethylation and inhibition of cell proliferation (Wales et al., 1995) .
To date, to the best of our knowledge, 15 solid tumor cases or cell lines carrying homozygous deletions have been sequenced and reported (Canning and Dryja, 1989; Tadokoro et al., 1992; Murata et al., 1994; Pomykala et al., 1994; Kohno et al., 1996; Inoue et al., 1997; Sekido et al., 1998; Nishioka et al., 2000; Shigemitsu et al., 2001; Tamura et al., 2002) . As a result, short direct repeats were found at the breakpoints in seven cases, while repetitive sequences such as long interspersed nuclear elements (LINEs) and Alu sequences appeared to be involved in five cases. There is one report describing potential involvement of inverted repeats. In the present case, 2 bp microhomology was found at the breakpoints, suggesting the possibility of doublestrand break-induced repair in the process generating interstitial deletion (Chen and Kolodner, 1999) . Alternatively, two pairs of short inverted repeats encompassing each end of the homozygous deletion may have mediated the interstitial deletion by forming a stem loop at the points of breakage.
The human genome project is about to complete sequencing the whole human genome. During the course of this study, sequence information of the genetic region of special interest to us was also considerably accumulated. However, sequences of the majority of BACs assigned still consist of unordered pieces of fragments with gaps of uncertain length. In addition, the order of genes contained in the contigs had been changed repeatedly through revisions to the database. Our study provides supplementary information, which firmly establishes the order of genes in this region as cen-PITPN-SKIP-MYO1C-CRK-14-3-3e-LOST1-tel.
In conclusion, together with our previous observation, this study provides further evidence for the presence of a putative tumor suppressor gene within a close proximity to the homozygous deletion at 17p13.3. The findings described here should serve as an important foundation for future efforts toward the identification of the putative tumor suppressor gene at 17p13.3, molecular cloning of which should shed light on the molecular mechanisms of lung carcinogenesis, considering that LOH in this region has been shown to occur earlier than that of the p53 locus (Konishi et al., 1998; Yatabe et al., 2000) .
Materials and methods
Tissue specimens and lung cancer cell lines
Lung cancer specimens together with uninvolved lung tissues were collected from surgical or necropsy cases (14 SCLCs, 54 adenocarcinomas, 28 squamous cell carcinomas and four large cell carcinomas). Adult and fetal tissues from various types of organs were obtained during necropsy and elective abortion, respectively. All tissues were quickly frozen in liquid nitrogen and stored at À801C until analysis. A total of 65 lung cancer cell lines (32 SCLCs, 19 adenocarcinomas, seven squamous cell carcinomas, two adenosquamous cell carcinomas and five large cell carcinomas) were analysed in this study.
YAC/BAC map construction
Identification of YAC/BAC clones was conducted by PCR screening of CEPH 'A' Human YAC DNA Pools (ResGen), CITB Human BAC DNA Pools Release IV (ResGen), and Down-to-the-Well Human BAC DNA Pools Release I (Genome Systems, Inc.) according to the manufacturers' instructions. The STS markers used for the screening were 14-3-3e exon 1, CRK exon 3 and D17S1174. YAC manipulation was performed according to standard procedures, and BACs were prepared following the instructions of the suppliers. YAC/BAC insert end sequences were determined by direct sequencing (BACs) or inverse PCR (YACs and BACs) to generate new STS markers corresponding to each of their ends. YAC/BAC end markers were analysed by PCR using the Human Chromosome 17 Regional Mapping Panel (NIGMS Human Genetic Mutant Cell Repository) to confirm their localization at 17p13.3. Alignment of YAC/BAC clones was done by PCR using markers corresponding to exons of the 14-3-3e and CRK genes, D17S1174 and the YAC/BAC insert end sequences.
PCR amplification of STS markers corresponding to the end of YAC/BAC inserts as well as to regions harboring 442O5-MluI and 442O5-NotI were carried out with the aid of primer pairs described in Table 1 . STS markers for exons were designed to include intron and/or untranslated regions in addition to the ORF sequence. Detailed information regarding PCR conditions is available upon request.
Restriction enzyme mapping
DNAs derived from three BACs were digested with restriction enzymes, processed for pulsed-field gel electrophoresis (PFGE) using clamped homogeneous electric field (CHEF)-DR II apparatus (BioRad). Agarose gels (1%) were run at 180 V in 0.5 Â TBE at 141C for 15 h with a pulse time from 1 to 5 s. After electrophoresis, the gels were blotted and the filters were hybridized with cDNA probes as well as BAC insert end probes according to the standard protocol.
For subcloning of the sequence around the MluI site on 442O5, a HindIII fragment, which was shown to contain an MluI site in double digestion with HindIII and MluI, was isolated and inserted into pBluescriptII SK(À). Subcloning of the NotI site on 442O5 was carried out in the same manner.
cDNA library screening
Human Lung 5 0 -STRETCH cDNA Library (Clontech) as well as Human Fetal Brain 5 0 -STRETCH PLUS cDNA Library (Clontech) was screened with predicted exon probes. Genomic regions, which were predicted as exons by a minimum of two in four publicly available on-line programs, GENSCAN, Grail (Ver. 3.1), FGENESH (Ver. 1.1) and HMMgene (Ver. 1.1), were considered as predicted exons (PE1-PE4). PE1-PE4 were amplified from gDNA using four sets of primer pairs: PE1-F: 5 0 -GGGAATGGGGAGGAAGAATG and PE1-R: 5 0 -TCAGGATCCTGAGCCTTTCT; PE2-F: 5 0 -GTCCAGCAT-TTCCCAACAGA and PE2-R: 5 0 -CTGGAACAAAGAC-CAGCACT; PE3-F: 5 0 -TCCTGTTCTCTTCACTGCTC and PE3-R: 5 0 -CTGCTTTGTAACAGAGGGCA and PE4-F: 5 0 -ATGAAGCTGACCCACAGCCT and PE4-R: 5 0 -CTGTGA-AGTTGACGGTCACG. The resultant PCR products (PE1-PE4: 1174, 500, 190 and 1375 bp in size) were cloned into plasmids and prepared as probes for further analysis.
Cloning of LOST1 gene
Three cDNA clones corresponding to Hs. 146059 (LOST1) were purchased from Stratagene. Exon-connection PCR was performed to extend the sequence of LOST1 exon 1 toward 5 0 direction with either of the following three forward primers generated on the provisional exon 1: LOST1-exon1F1: 5 0 -CGCATTCTTCTCTCTGCTCT; LOST1-exon1F2: 5 0 -GAACTCAGCTGGCTTGAGAA and LOST1-exon1F3: 5 0 -TGTCCCAGCCTGGAGCTGCA, together with a reverse primer PE4-R. 5 0 and 3 0 RACE were also carried out to identify each end of the LOST1 gene essentially as described by Frohman (Frohman, 1993) . cDNA synthesis for generating a template for 5 0 RACE of LOST1 was conducted using LOST1-exon1R3: 5 0 -GCCTTGGTGAGGAGTATCTC. 5 0 RACE was then carried out using a forward primer RACE-B: 5 0 -GGAT(C) 13 in combination with reverse primers, LOST1-exon1R2: 5 0 -TGAAGGAAACTCGGACTGCA and LOST1-exon1R1: 5 0 -GTGCTGCTGAGAGCACAGAT for the first and second rounds of PCR, respectively. With regard to 3 0 RACE of LOST1, a primer Qt: 5 0 -CACGCGTCGTCTAGTAC-GAC(T) 17 was used for cDNA template synthesis, and two rounds of PCR were carried out with either LOST1-exon3F1: 5 0 -GGACCAGGTTTGGGAATACA and LOST1-exon3F2: 5 0 -TTTGTCCCATCAGGACCCTC, or LOST1-exon3F3: 5 0 -CCTGGAGGAGAAAGCCATTC. The reverse primer used for 3 0 RACE was Qo: 5 0 -CACGCGTCGTCTAGTACGAC. In RNase protection assay, a 489 bp fragment amplified by PCR with a primer pair PE2-F and LOST1-exon1R1 was subcloned into pBluescriptII SK(À), and used as a template for generating riboprobes by in vitro transcription. In vitro transcription from T7 promoter and RNase protection assay were performed using RiboQuant RPA Kit (Pharmingen) according to the manufacturer's instructions.
Southern blot and Northern blot analyses
Extraction of gDNA and total RNA from cell lines and tissues were conducted according to standard procedures. Southern blot analysis was performed using 5 mg of gDNAs digested with EcoRI. A LOST1 cDNA probe for Southern blot hybridization spanning the entire ORF was generated by RT-PCR with the aid of a primer pair, LOST1-exon1F2 and LOST1-exon3R1: 5 0 -TTTCTTGTCAGATGGGGGCT. Northern blot analysis was performed using 10 mg of total RNA according to standard procedures. CRK cDNA probe was generated with CRK-exon3F2: 5 0 -CGTCTGCTGGAT-CAACAGAA and CRK-exon3R2: CAGGGTAAGCAGTG-TGTAAC. The 14-3-3e cDNA probe used in this study was identical to that described previously (Konishi et al., 2002) .
Expressional analysis of LOST1
Expression of LOST1 was analysed by using both the RT-PCR and quantitative real-time RT-PCR techniques. Oligonucleotide primers used were LOST1-exon1F4: 5 0 -TATGCC-CAAGACCAAGAAGC and PE3-R. RT-PCR amplification with RNAs from various organs was carried out with 35 cycles (95, 63 and 721C, each for 30 s) after the initial denaturation step (951C for 3 min) in the presence of 5% DMSO. For the analysis of the LOST1 expression in lung cancer specimens, RT-PCR was carried out under the same conditions, except for amplification with 40 instead of 35 cycles. Quantitative real-time RT-PCR analysis was conducted with the aid of ABI Prism 7900HT (Applied Biosystems) and SYBR Green PCR Master Mix (Applied Biosystems) according to the manufacturer's instructions. Amplification was performed with 50 cycles (951C for 15 s, 651C for 30 s and 721C for 30 s), after the initial denaturation step (951C for 10 min), and followed by dissociation curve analysis. Expression of LOST1 was normalized to expression of 18S ribosomal RNA, which was obtained by real-time RT-PCR with oligonucleotide primers: 5 0 -AATCAGGGTTCGATTCCGGA and 5 0 -CCAAGATCCA-ACTACGAGCT.
Methylation analysis of the LOST1 gene DNA methylation analysis based on the sodium bisulfite conversion technique was performed as described previously (Osada et al., 2001) . Oligonucleotide primers used for the PCR amplification after bisulfite conversion were 5 0 -GTTTGAGTTTTTTTGGGAAGAGG and 5 0 -ACTAAA-ACCTACCTACTACCCC. The resultant PCR products encompassing the 5 0 end of the LOST1 transcripts shown in Figure 3a harbored five CpG sites, and corresponded to nucleotides 191840-191666 of AC032044.5 of BAC 818O24.
Mutation search
In RT-PCR-SSCP analysis, the ORF of 768 bp (14-3-3e) and 915 bp (CRK) were divided into three and four fragments, respectively. The primer pairs utilized to amplify three 14-3-3e gene fragments were as follows: 14-3-3e-fragment1F: 5 0 -AGACCCTGCCGGAGCCGCTG, 14-3-3e-fragment1R: 5 0 -GCTCAGTCTCAACCATTTGCCG; 14-3-3e-fragment2F: 5 0 -CAAGCTAAAAATGATTCGGGA, 14-3-3e-fragment2R: 5 0 -GAGAGCAAGACCTAAGCGAA; 14-3-3e-fragment3F: 5 0 -ACTTCCACCAACGCATCCTA, 14-3-3e-fragment3R: 5 0 -TTTCTCTTGTTGGCTTATGTC. Primer pairs used for the amplification of four CRK fragments were as follows: CRK-fragment1F: 5 0 -GGCGGCGGCACCCCAGCGTT, CRKfragment1R: 5 0 -TGGGCGGGCGACGGTGGCAC; CRK-fragment2F: 5 0 -TACATCATCAACAGCAGCGG, CRK-fragment 2R: 5 0 -CCCGGATTCTCAAGATGTCT; CRK-fragment 3F: 5 0 -GATCTTCCCTTTAAGAAAGG, CRK-fragment3R: 5 0 -CCATTCTGGAGGTTAGGGAG; CRK-fragment4F: 5 0 -AACCCAGCGTCAACACTCCG, CRK-fragment4R: 5 0 -CCC-ATCTGTCAGCAAAACTG. LOST1 was analysed by direct sequencing of each exon using the following primers: LOST1-exon1F2 and PE1R for exon 1; LOST1-intron1F: 5 0 -TAGAGTGTGGGCTGCCATGG and LOST1-intron2R: 5 0 -TTCCTCCTCTCCAAGGAGCT for exon 2 and LOST1-intron2F: 5 0 -ATCCTCCAGTCAGGGACTTG and LOST1-exon3R1 for exon 3.
Definition of the breakpoints of the homozygous deletion
Primer pairs for five STS markers within CRK intron 2 were designed referring to the draft sequence of BAC 818O24. Detailed information will be provided upon request. PCR amplification of the 1918 bp region of the fused breakpoints owing to the homozygous deletion in ACC-LC-48 and ACC-LC-52 was carried out with the aid of the following primers: CRK-intron2F1: 5 0 -GATGTCCCCTGTGTAGTGAA and PE1-F.
Duplex PCR
Duplex PCR amplifications were performed using gDNA, followed by electrophoresis on 3% agarose gels. The following oligonucleotide primers were used for amplification: CRKexon3F: 5 0 -ACAGTTTTGCTGACAGATGGG and CRKexon3R: 5 0 -GGAATGGAGCAGTTCAGTCTA; p53-intron6F: 5 0 -TGCTTGCCACAGGTCTCC and p53-intron7R: 5 0 -ATCGGTAAGAGGTGGGCC; D17S1174-F: 5 0 -TGCA-CAGGTACCCCAGAACT and D17S1174-R: 5 0 -CCATTA-CCTCAGTAAGTGAAC; p53-intron7F: 5 0 -TGGGAGTA-GATGGAGCCT and p53-exon8R: 5 0 -TCTCCCAGGACAG-GCACAAA; CRK-intron2BP: 5 0 -CAGAGCTGTAAGAAG-CTCCT and LOST1-exon1F2; and p53-exon7F: 5 0 -GTAA-CAGTTCCTGCATGGGC and p53-exon8R.
